Research Assistant Professor of Pharmacology
Bio
Nurmaa K. Dashzeveg, PhD, is a leading researcher in breast cancer metastasis, focusing on therapeutic approach to block breast cancer metastasis by investigating new modification of glycoproteins on circulating tumor cells. With a background in DNA damage response and tumor suppressor p53 from Tokyo Medical and Dental University and Tokyo Jikei University School of Medicine, her research aims to develop targeted treatments that selectively eliminate cancer cells.
Chemotherapy remains the major standard of care for metastatic triple negative breast cancer (TNBC). However, TNBC often develops resistance to chemotherapy, which accelerates the formation of circulator tumor cells (CTCs) clusters. In this proposal, we aim to investigate the molecular mechanisms of chemotherapy resistance associated CTC cluster formation, and to develop new therapeutic approach to block CTC cluster formation and inhibit metastasis of breast cancer.
Nurmaa K. Dashzeveg, PhD
Northwestern University Feinberg School of Medicine
Newly funded researchers pursuing high-risk, high-reward breast cancer studies in their first or second academic positions.
Past
Early Investigator
Abde Abukhdeir, PhD
The molecular variants that lead or contribute to drug resistance in breast cancer
Past
Early Investigator
Nan Chen, MD
Discovering novel biomarkers of therapy response and resistance in metastatic triple-negative breast cancer patients
Past
Early Investigator
Peiwen Chen, PhD
Targeting macrophage reprogramming in brain metastatic breast cancer
Why your gift matters
Your gift helps researchers test bold ideas, generate critical data, and take the first steps toward the next major advancement in breast cancer treatment and care.Together, we can accelerate discoveries that save lives.
